P1.12A.07 A Phase 1 Study of TY-9591 in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients with EGFR Positive Mutation.
Back to course
Pdf Summary
Asset Subtitle
Baohui Han
Meta Tag
Speaker Baohui Han
Topic Metastatic NSCLC – Targeted Therapy
Keywords
TY-9591
EGFR mutations
non-small cell lung cancer
third-generation TKI
brain metastases
L858R mutations
dose escalation
safety and efficacy
progression-free survival
osimertinib
Powered By